Key facts
- Notable investors include Shenzhen Capital Group, Shanghai Healthcare Capital, Shenzhen Huaqian Equity Investment Fund Management, Invengo Information Technology Company, Ltd. — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for AlphaMol
- ·The full record, as it builds
Funding rounds
No funding rounds for AlphaMol are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AlphaMol
Developer of biological computing technologies intended to speed up modern drug discovery. The company's technologies integrated computation biology, artificial intelligence, and other new technologies in experimental drug screening to develop front-end biological computing methods, coupled with originally innovative biotechnologies, enabling customers in the medical industry to expedite the screening and designing of potent drug candidates.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2020
- Website
- alphamol.com/
- Ownership
- Privately Held (backing)
AlphaMol doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AlphaMol shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AlphaMol in its N-PORT filings yet. We sweep new filings monthly.